Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. GSK has a long-standing interest in inhibition of TRPV4 as a novel approach for the treatment of pulmonary edema associated with congestive heart failure. Herein, we present work related to the discovery of two pre-clinical candidates from distinct chemical series.

Discovery of Hydroxy-core spirocarbamates and pyrrolidine sulfonamides as transient receptor potential vanilloid-4 (TRPV4) antagonists

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.